Sanofi shares fall on €9.5bn haemophilia purchase

French healthcare group Sanofi has agreed to buy US haemophilia specialist Bioverativ for $11.6bn (€9.5bn), its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases.

French healthcare group Sanofi has agreed to buy US haemophilia specialist Bioverativ for $11.6bn (€9.5bn), its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases.

Sanofi shares fell almost 3.75% at one stage in Paris trade in the latest session, making the stock the worst performer on France’s benchmark CAC-40 index and several analysts deemed the deal expensive.